Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.

Signoriello, E

Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis. [electronic resource] - Multiple sclerosis (Houndmills, Basingstoke, England) 06 2016 - 921-5 p. digital

Publication Type: Journal Article

1477-0970

10.1177/1352458515604381 doi


Adult
Female
Humans
Immunosuppressive Agents--adverse effects
Leukocyte Count
Lymphocytosis--blood
Magnetic Resonance Imaging
Male
Multiple Sclerosis, Chronic Progressive--blood
Multiple Sclerosis, Relapsing-Remitting--blood
Natalizumab--adverse effects
Predictive Value of Tests
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
Young Adult